167. Marfan syndrome
19 clinical trials,   38 drugs   (DrugBank: 10 drugs),   10 drug target genes,   49 drug target pathways

Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01949233
(ClinicalTrials.gov)
October 20136/8/2013The Oxford Marfan TrialA Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance ImagingMarfan SyndromeDrug: Irbesartan 150-300mg capsules daily for 6 months;Drug: Doxycycline 100-200mg capsules daily for 6 months;Drug: Doxycycline placebo capsules daily for 6 months;Drug: Irbesartan placebo capsules daily for 6 monthsUniversity of OxfordOxford University Hospitals NHS TrustRecruiting13 YearsN/ABoth56Phase 2United Kingdom
2EUCTR2010-023612-14-GB
(EUCTR)
08/03/201320/12/2012The Oxford Marfan Trial A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 Marfan syndrome.
MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Clinical Trials and Research GovernanceNULLNot Recruiting Female: yes
Male: yes
56Phase 2United Kingdom
3EUCTR2010-019302-16-GB
(EUCTR)
13/09/201017/08/2010A prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndromeA prospective, randomised, placebo-controlled, double blind, multi-centre study of the effects of Irbesartan on aortic dilatation in Marfan syndrome - The AIMS Study Marfan SyndromeRoyal Brompton and Harefield NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
490Phase 3United Kingdom
4NCT01715207
(ClinicalTrials.gov)
June 201024/10/2012Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFSComparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With AtenololMarfan SyndromeDrug: Aliskiren;Drug: AtenololSamsung Medical CenterNULLCompleted14 Years55 YearsAll30Phase 3Korea, Republic of
5NCT00782327
(ClinicalTrials.gov)
June 200929/10/2008Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersRandomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersMarfan SyndromeDrug: Losartan;Drug: PlaceboUniversity Hospital, GhentAgentschap voor Innovatie door Wetenschap en TechnologieRecruiting10 YearsN/ABoth174Phase 3Belgium
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-005862-10-BE
(EUCTR)
29/05/200907/01/2009Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. Marfan syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: Cozaar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
University Hospital GhentNULLNot RecruitingFemale: yes
Male: yes
Belgium
7EUCTR2008-001462-81-IT
(EUCTR)
27/10/200817/03/2008Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDEffects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND Marfan Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: LORTAAN*28CPR RIV DIV 50MG
INN or Proposed INN: Losartan
Trade Name: LOBIVON*28CPR 5MG
INN or Proposed INN: Nebivolol
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
Phase 3Italy
8NCT01145612
(ClinicalTrials.gov)
October 200815/6/2010Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan SyndromeA Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome.Marfan SyndromeDrug: Losartan;Drug: AtenololForteza, Albert, M.D.Ministry of Health, SpainActive, not recruiting5 Years60 YearsBoth140Phase 3Spain
9NCT00763893
(ClinicalTrials.gov)
September 200830/9/2008Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan SyndromeMulticenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan SyndromeMarfan SyndromeDrug: placebo;Drug: LosartanAssistance Publique - Hôpitaux de ParisNULLTerminated10 YearsN/ABoth303Phase 3France
10NCT00683124
(ClinicalTrials.gov)
July 200821/5/2008Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan PatientsEffects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.Marfan SyndromeDrug: Losartan and nebivolol;Drug: Losartan;Drug: NebivololIRCCS Policlinico S. MatteoMerck Sharp & Dohme Corp.;Menarini GroupRecruiting12 Months55 YearsBoth291Phase 3Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2007-001125-97-ES
(EUCTR)
20/05/200803/12/2007Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Trade Name: cozaar 50
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: blokium 50
INN or Proposed INN: ATENOLOL
Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: BLOKIUM 50 mg comprimidos
INN or Proposed INN: ATENOLOL
alberto fortezaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
12NCT00593710
(ClinicalTrials.gov)
January 20083/1/2008Losartan Versus Atenolol for the Treatment of Marfan SyndromeA Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan;Drug: AtenololUniversity of British ColumbiaHeart and Stroke Foundation of CanadaCompleted12 Years25 YearsBoth17Phase 2Canada
13NCT00723801
(ClinicalTrials.gov)
October 200725/7/2008Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan SyndromeEffects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan SyndromeMarfan SyndromeDrug: Atenolol;Drug: LosartanBrigham and Women's HospitalBoston Children’s HospitalCompleted25 YearsN/AAll40Phase 3United States
14NCT00651235
(ClinicalTrials.gov)
February 20073/3/2008A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeA Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan and Atenolol or Propranolol;Drug: Atenolol or PropranololNational Taiwan University HospitalNULLRecruiting1 YearN/ABoth44Phase 2Taiwan
15NCT00429364
(ClinicalTrials.gov)
January 200729/1/2007Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart NetworkTrial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)Marfan SyndromeDrug: Losartan Potassium;Drug: AtenololNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan FoundationCompleted6 Months25 YearsAll608Phase 3United States;Belgium;Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2006-003991-37-BE
(EUCTR)
13/12/200606/12/2006Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan TrialTrial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial Marfan syndrome
MedDRA version: 8.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
University Hospital GentNULLNot RecruitingFemale: yes
Male: yes
600Belgium
17NCT01295047
(ClinicalTrials.gov)
July 200611/2/2011Comparison of Medical Therapies in Marfan Syndrome.Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover TrialMarfan SyndromeDrug: Atenolol;Drug: VERAPAMIL;Drug: PerindoprilCardiff UniversityNULLCompleted16 Years60 YearsBoth18Phase 4United Kingdom
18EUCTR2005-000749-13-GB
(EUCTR)
30/07/200520/06/2005 A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. Marfan SyndromeCardiff UniversityNULLNot Recruiting Female: yes
Male: yes
60Phase 4United Kingdom
19NCT00485368
(ClinicalTrials.gov)
January 200411/6/2007Angiotensin Converting Enzyme Inhibitors in Marfan SyndromeThe Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.Marfan SyndromeDrug: Coversyl (perindopril)Bayside HealthBaker Heart Research Institute;The AlfredCompleted18 Years40 YearsBoth17Phase 3NULL